Prognostic Value of Tumor-infiltrating Lymphocytes in Estrogen Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2021 Oct 21

PMID 34671471

Citations 8

Authors

Chikako Honda

Sasagu Kurozumi

Ayaka Katayama

Bishoy Hanna-Khalil

Kei Masuda

Yuko Nakazawa

Misato Ogino

Sayaka Obayashi

Reina Yajima

Takaya Makiguchi

Tetsunari Oyama

Jun Horiguchi

Ken Shirabe

Takaaki Fujii

Affiliations

Soon will be listed here.

Abstract

Tumor-infiltrating lymphocytes (TILs) are a significant prognostic factor in triple-negative breast cancer. However, the clinicopathological significance of TILs in estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer remains unclear. The purpose of the present study was to evaluate the role of TILs in the prognosis of ER-positive and HER2-negative breast cancer. A total of 65 consecutive patients with ER-positive and HER2-negative breast cancer were examined. TILs in stromal tissue (str-TILs) were graded using the International TILs Working Group criteria. The association between several clinicopathological factors and TIL grade were investigated, and the prognostic impact of TILs was compared between luminal A-like and luminal B-like breast cancer. A total of 51 patients (78.5%) had low-grade (0-10%), 11 (16.9%) had intermediate (10-40%) and 3 (4.6%) had high-grade (40-90%) str-TIL levels. There was a significant association between high levels of Ki67 expression and a high str-TIL count. Relapse-free survival was significantly worse in patients with luminal B-like cancer compared with that in patients with luminal A-like cancer. Patients with an intermediate or high str-TIL count had a better prognosis compared with those with a low str-TIL count. All patients with luminal B-like cancer and intermediate or high str-TIL levels developed no recurrence during follow-up. In conclusion, there was a significant correlation between high-grade str-TIL levels and high tumor cell proliferation rate, as well as high levels of Ki67 expression.

Citing Articles

Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer.

Narusawa E, Kurozumi S, Katayama A, Koibuchi Y, Ogawa A, Takata D Med Mol Morphol. 2024; 57(3):177-184.

PMID: 38619618 DOI: 10.1007/s00795-024-00386-z.

Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.

Arqueros C, Gallardo A, Vidal S, Osuna-Gomez R, Tibau A, Lidia Bell O Int J Mol Sci. 2024; 25(5).

PMID: 38473874 PMC: 10932208. DOI: 10.3390/ijms25052627.

Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence.

Makhlouf S, Wahab N, Toss M, Ibrahim A, Lashen A, Atallah N Br J Cancer. 2023; 129(11):1747-1758.

PMID: 37777578 PMC: 10667537. DOI: 10.1038/s41416-023-02451-3.

Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study.

Sun T, Wang T, Li X, Wang H, Mao Y Front Oncol. 2023; 13:1148228.

PMID: 37409261 PMC: 10318431. DOI: 10.3389/fonc.2023.1148228.

Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies.

Stevenson V, Klahn S, LeRoith T, Huckle W Front Vet Sci. 2023; 9:1046636.

PMID: 36686160 PMC: 9853198. DOI: 10.3389/fvets.2022.1046636.

References

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

Kurozumi S, Yamaguchi Y, Matsumoto H, Kurosumi M, Hayashi S, Fujii T . Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS One. 2019; 14(5):e0217279. PMC: 6528995. DOI: 10.1371/journal.pone.0217279. View

Dudley J, Lin M, Le D, Eshleman J . Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016; 22(4):813-20. DOI: 10.1158/1078-0432.CCR-15-1678. View

Tower H, Ruppert M, Britt K . The Immune Microenvironment of Breast Cancer Progression. Cancers (Basel). 2019; 11(9). PMC: 6769749. DOI: 10.3390/cancers11091375. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Haricharan S, Bainbridge M, Scheet P, Brown P . Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat. 2014; 146(1):211-20. PMC: 4061465. DOI: 10.1007/s10549-014-2991-x. View

Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J . Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer. 2017; 17(1):354. PMC: 5441075. DOI: 10.1186/s12885-017-3331-4. View

Fujimoto Y, Watanabe T, Hida A, Higuchi T, Miyagawa Y, Ozawa H . Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Breast Cancer. 2019; 26(6):738-747. DOI: 10.1007/s12282-019-00977-0. View

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View

10.

Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M . Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS One. 2018; 13(8):e0201846. PMC: 6078304. DOI: 10.1371/journal.pone.0201846. View

11.

Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16):2784-95. PMC: 2881855. DOI: 10.1200/JCO.2009.25.6529. View

12.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D . Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25(8):1544-50. DOI: 10.1093/annonc/mdu112. View

13.

Pereira B, Chin S, Rueda O, Vollan H, Provenzano E, Bardwell H . The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016; 7:11479. PMC: 4866047. DOI: 10.1038/ncomms11479. View

14.

Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T . Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. Sci Rep. 2019; 9(1):1583. PMC: 6367461. DOI: 10.1038/s41598-018-38272-1. View

15.

Montagna E, Vingiani A, Maisonneuve P, Cancello G, Contaldo F, Pruneri G . Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast. 2017; 34:83-88. DOI: 10.1016/j.breast.2017.05.009. View

16.

Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y . Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. J Natl Cancer Inst. 2017; 110(2). PMC: 6298573. DOI: 10.1093/jnci/djx137. View

17.

Marabelle A, Le D, Ascierto P, Di Giacomo A, De Jesus-Acosta A, Delord J . Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019; 38(1):1-10. PMC: 8184060. DOI: 10.1200/JCO.19.02105. View

18.

Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R . Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer. 2011; 19(4):309-14. DOI: 10.1007/s12282-011-0291-4. View

19.

Kurozumi S, Matsumoto H, Kurosumi M, Inoue K, Fujii T, Horiguchi J . Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett. 2019; 17(3):2647-2656. PMC: 6396218. DOI: 10.3892/ol.2019.9938. View

20.

Bates J, Derakhshandeh R, Jones L, Webb T . Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018; 18(1):556. PMC: 5948714. DOI: 10.1186/s12885-018-4441-3. View